ReviewGlobal cardiology science & practice2012
Heart failure with preserved ejection fraction.
Review in Global cardiology science & practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study.European journal of medical research · 2025Trial
- Levosimendan in Europe and China: An Appraisal of Evidence and Context.European cardiology · 2021Review
- Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF.Global cardiology science & practice · 2019Article
- Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction.Frontiers in physiology · 2019Article
- The expanding role of implantable devices to monitor heart failure and pulmonary hypertension.Nature reviews. Cardiology · 2018Review
- New echocardiographic parameters in the diagnosis of heart failure with preserved ejection fraction.The international journal of cardiovascular imaging · 2018Article
- NEAT HFpEF: Organic nitrates fail to deliver.Global cardiology science & practice · 2016Article
- Towards 'Eternal Youth' of cardiac and skeletal muscle.Global cardiology science & practice · 2015Article
- PARIS: A good start for exercise in HFPEF.Global cardiology science & practice · 2014Article
- TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?Global cardiology science & practice · 2013Article
- ALDO-DHF & Paramount.Global cardiology science & practice · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) has recently emerged as a major cause of cardiovascular morbidity and mortality. Contrary to initial beliefs, HFpEF is now known to be as common as heart failure with reduced ejection fraction (HFrEF) and carries an unacceptably high mortality rate. With a prevalence that has been steadily rising over the past two decades, it is very likely that HFpEF will represent the dominant heart failure phenotype over the coming few years. The scarcity of trials in this semi-discrete form of heart failure and lack of unified enrolment criteria in the studies conducted to date might have contributed to the current absence of specific therapies. Understanding the epidemiological, pathophysiological and molecular differences (and similarities) between these two forms of heart failure is cornerstone to the development of targeted therapies. Carefully designed studies that adhere to unified diagnostic criteria with the recruitment of appropriate controls and adoption of practical end-points are urgently needed to help identify effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.